Additional Study Information: The purpose of the study is to test the safety of an investigational study drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody) administered alone and in combination with nivolumab, and in comparison to Ipilimumab. This study will investigate how research subjects with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose of BMS-986218 alone and in combination with nivolumab, in cancer research subjects. This is the first study in which BMS-986218 will be administered to humans. Nivolumab and ipilimumab have been administered to and is approved for human use in multiple tumor types.